AC Immune (ACIU) Research & Development (2015 - 2026)

AC Immune (ACIU) has 12 years of Research & Development data on file, last reported at -$15.0 million in Q1 2026.

• On a quarterly basis, Research & Development rose 15.28% year-over-year to -$15.0 million in Q1 2026; TTM through Mar 2026 was -$65.0 million, a 9.01% increase from a year earlier, with the FY2025 full-year figure at -$68.1 million, up 4.7% from the prior year.
• Research & Development for Q1 2026 stood at -$15.0 million, down from -$13.3 million in the prior quarter.
• Over the last five years, Research & Development for ACIU reached as high as -$13.3 million in Q4 2025 and fell as low as -$20.3 million in Q2 2025.
• Historically, Research & Development has averaged -$16.3 million across 5 years, with a median of -$16.3 million in 2025.
• Across the five-year window, Research & Development gained 28.01% in 2022 and fell 24.54% in 2024, its largest moves.
• Year by year, Research & Development stood at -$15.7 million in 2022, then slipped by 5.08% to -$16.5 million in 2023, then decreased by 9.15% to -$18.0 million in 2024, then climbed by 26.24% to -$13.3 million in 2025, then retreated by 12.84% to -$15.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$15.0 million in Q1 2026, -$13.3 million in Q4 2025, and -$16.3 million in Q3 2025.